US-based medical device company Mitralign has finished enrolling patients in the early feasibility study, Scout, to test its Trialign System for transcatheter repair of functional tricuspid regurgitation (FTR).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to Mitralign CEO Rick Geoffrion, the company has enrolled an initial group of fifteen people marking the initiation of the first US feasibility test to evaluate the transcathether device in treating patients suffering from tricuspid regurgitation.

NewYork-Presbyterian / Columbia University Medical Center Interventional Echocardiography director and Scout study principal investigator Rebecca Hahn said: “The clinical community is excited about the potential opportunity to provide a breakthrough non-surgical option for patients with tricuspid regurgitation.

“We know the number of people suffering with tricuspid regurgitation is much bigger than previously reported, and we are in the nascent stages of treating this large, unaddressed population.

“The Trialign System leaves behind a very small footprint, so we believe this device has the potential to be a front line solution for patients with functional TR.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

"The Trialign System leaves behind a very small footprint, so we believe this device has the potential to be a front line solution for patients with functional TR."

The tricuspid valve is located between the right atrium and the right ventricle which opens to allow blood to be pumped from the right atrium in to the right ventricle.

The valve closes as soon as the blood makes its way through it so that it cannot pass back.

Tricuspid regurgitation (TR) occurs when the tricuspid valve cannot open and close properly, causing blood to flow backward into the right atrium.

TR can cause heart enlargement and heart failure if it is not treated.

Image: Echocardiography hinting at severe tricuspid regurgitation. Photo: courtesy of AMC Echolab via Wikipedia.